Compass Therapeutics, Inc. (CMPX) — Financial statements
Income statement, balance sheet, and cash flow for Compass Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00↓100.0% | 0.85 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 1 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -1↓273.2% | 0.85 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 56↑32.2% | 42↑11.1% | 38↑27.1% | 30↑47.5% | 20 | |
| General & Administrative Expenses | 17↑11.5% | 15↑23.6% | 12↑5.0% | 12↑6.7% | 11 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 17↑11.5% | 15↑23.6% | 12↑5.0% | 12↑6.7% | 11 | |
| Other Expenses | -1 | 0.00 | 0.00 | 0.00↓100.0% | 51 | |
| Operating Expenses | 71↑24.2% | 57↑14.1% | 50↑20.9% | 42↓49.1% | 82 | |
| Total Costs & Expenses | 73↑26.7% | 57↑14.1% | 50↑20.9% | 42↓49.1% | 82 | |
| Operating Results | ||||||
| Operating Income | -73↓28.6% | -57↓12.4% | -50↓20.9% | -42↑49.1% | -82 | |
| Depreciation & Amortization | 1↓16.0% | 2↓7.2% | 2↓0.7% | 2↑17.2% | 2 | |
| EBITDA | -71↓30.1% | -55↓13.2% | -48↓21.9% | -40↑50.4% | -80 | |
| EBIT | -73↓28.6% | -57↓12.4% | -50↓20.9% | -42↑49.1% | -82 | |
| Interest & Other Income | ||||||
| Net Interest Income | 6↓13.0% | 7 | 0.00 | 0.00↑100.0% | -0.34 | |
| Interest Income | 6↓13.0% | 7 | 0.00↓100.0% | 2↑8037.9% | 0.03 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 2↑537.8% | 0.37 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -0.07 | |
| Other Income / Expenses | 6↓12.4% | 7↓7.9% | 8↑223.8% | 2↑912.7% | -0.30 | |
| Income Before Tax | -66↓34.7% | -49↓16.2% | -42↓8.3% | -39↑52.3% | -82 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -66↓34.7% | -49↓16.2% | -42↓8.3% | -39↑52.3% | -82 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -66↓34.7% | -49↓16.2% | -42↓8.3% | -39↑52.3% | -82 | |
| Bottom-Line Net Income | -66↓34.7% | -49↓16.2% | -42↓8.3% | -39↑52.3% | -82 | |
| EPS (Basic) | -0.42↓16.7% | -0.36↓9.1% | -0.33↑5.7% | -0.35↑73.3% | -1.31 | |
| EPS (Diluted) | -0.42↓16.7% | -0.36↓9.1% | -0.33↑5.7% | -0.35↑73.3% | -1.31 | |
| Weighted Average Shares | 158↑15.0% | 137↑7.9% | 127↑20.8% | 105↑67.3% | 63 | |
| Weighted Average Diluted Shares | 158↑15.0% | 137↑7.9% | 127↑20.8% | 105↑67.3% | 63 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.